Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
(NASDAQ: ROIV) Delayed: 39.77 -0.21 (0.53%)
Previous Close $39.98    52 Week High $ 
Open $40.11    52 Week Low $ 
Day High $40.71    P/E N/A 
Day Low $39.72    EPS $ 
Volume 32,200,469